136 related articles for article (PubMed ID: 34244783)
21. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation.
Krivoy N; Hoffer E; Tabak A; Elhasid R; Arush MW; Stein J; Yaniv I; Rowe JM
Pediatr Hematol Oncol; 2002; 19(1):31-7. PubMed ID: 11833485
[TBL] [Abstract][Full Text] [Related]
22. Individualizing oral busulfan dose after using a test dose in patients undergoing hematopoietic stem cell transplantation: pharmacokinetic characterization.
Effting C; de Moraes Arantes A; Queiroz Labre LV; Carneiro WJ; de Oliveira Neto JR; Bariani C; Rodrigues CR; Rodrigues AR; Cunha LC
Ther Drug Monit; 2015 Feb; 37(1):66-70. PubMed ID: 25588069
[TBL] [Abstract][Full Text] [Related]
23. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
[TBL] [Abstract][Full Text] [Related]
24. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
25. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients.
Watanabe E; Nishikawa T; Ikawa K; Yamaguchi H; Abematsu T; Nakagawa S; Kurauchi K; Kodama Y; Tanabe T; Shinkoda Y; Matsumoto K; Okamoto Y; Takeda Y; Kawano Y
Int J Hematol; 2015 Nov; 102(5):611-6. PubMed ID: 26243625
[TBL] [Abstract][Full Text] [Related]
26. Pediatric patients undergoing hematopoietic stem cell transplantation can greatly benefit from a novel once-daily intravenous busulfan dosing nomogram.
Rhee SJ; Lee JW; Yu KS; Hong KT; Choi JY; Hong CR; Park KD; Shin HY; Song SH; Kang HJ; Lee H
Am J Hematol; 2017 Jul; 92(7):607-613. PubMed ID: 28370238
[TBL] [Abstract][Full Text] [Related]
27. Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation.
Abdel-Rahman SM; Casey KL; Garg U; Dalal J
Pediatr Transplant; 2016 May; 20(3):443-8. PubMed ID: 26854326
[TBL] [Abstract][Full Text] [Related]
28. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Dupuis LL; Sibbald C; Schechter T; Ansari M; Gassas A; Théorêt Y; Kassir N; Champagne MA; Doyle J
Biol Blood Marrow Transplant; 2008 May; 14(5):576-82. PubMed ID: 18410900
[TBL] [Abstract][Full Text] [Related]
29. Integration of modelling and simulation into the development of intravenous busulfan in paediatrics: an industrial experience.
Nguyen L
Fundam Clin Pharmacol; 2008 Dec; 22(6):599-604. PubMed ID: 19049661
[TBL] [Abstract][Full Text] [Related]
30. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
31. Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.
Nath CE; Earl JW; Pati N; Stephen K; Shaw PJ
Br J Clin Pharmacol; 2008 Jul; 66(1):50-9. PubMed ID: 18341668
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation.
Cremers S; Schoemaker R; Bredius R; den Hartigh J; Ball L; Twiss I; Vermeij P; Vossen J
Br J Clin Pharmacol; 2002 Apr; 53(4):386-9. PubMed ID: 11966670
[TBL] [Abstract][Full Text] [Related]
33. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
34. Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.
Veal GJ; Nguyen L; Paci A; Riggi M; Amiel M; Valteau-Couanet D; Brock P; Ladenstein R; Vassal G
Eur J Cancer; 2012 Nov; 48(16):3063-72. PubMed ID: 22742881
[TBL] [Abstract][Full Text] [Related]
35. Incorporation of GSTA1 genetic variations into a population pharmacokinetic model for IV busulfan in paediatric hematopoietic stem cell transplantation.
Nava T; Kassir N; Rezgui MA; Uppugunduri CRS; Huezo-Diaz Curtis P; Duval M; Théoret Y; Daudt LE; Litalien C; Ansari M; Krajinovic M; Bittencourt H
Br J Clin Pharmacol; 2018 Jul; 84(7):1494-1504. PubMed ID: 29469189
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation.
Oechtering D; Schiltmeyer B; Hempel G; Schwab M; Würthwein G; Mürdter T; Klingebiel T; Vormoor J; Gruhn B; Fleischack G; Boos J
Anticancer Drugs; 2005 Mar; 16(3):337-44. PubMed ID: 15711187
[TBL] [Abstract][Full Text] [Related]
37. Comparison of algorithms for oral busulphan area under the concentration-time curve limited sampling estimate.
Sjöö F; El-Serafi I; Enestig J; Mattsson J; Liwing J; Hassan M
Clin Drug Investig; 2014 Jan; 34(1):43-52. PubMed ID: 24178237
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients.
Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Oberg G; Bekassy A; Hassan M
Bone Marrow Transplant; 2001 Oct; 28(7):657-64. PubMed ID: 11704788
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of two software using Bayesian methods for monitoring exposure and dosing once-daily intravenous busulfan in paediatric patients receiving haematopoietic stem cell transplantation.
Lawson R; Paterson L; Fraser CJ; Hennig S
Cancer Chemother Pharmacol; 2021 Sep; 88(3):379-391. PubMed ID: 34021809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
